News

Treatment with Xolair (omalizumab), an approved therapy for allergic asthma and chronic spontaneous urticaria (CSU), was associated with strong symptom control in people with mast cell–mediated angioedema, according to a large real-world study. Benefits were observed regardless of whether patients experienced wheals, itchy skin bumps commonly known as…

On-demand treatment with Ekterly (sebetralstat), marketed by Kalvista Pharmaceuticals for hereditary angioedema (HAE), reduced anxiety associated with swelling attacks more quickly and effectively than a placebo in a recent study. “Moderate-to-extreme anxiety was common,” the researchers wrote, but it eased with treatment, particularly in patients who were…

Deucrictibant, an experimental oral small molecule from Pharvaris, delivers rapid relief when used on demand for acute attacks of hereditary angioedema (HAE) and can, over time, also reduce the frequency of the swelling that causes the attacks,…

Children as young as 2 years may soon have access to the first-ever oral treatment for sudden hereditary angioedema (HAE) attacks. New Phase 3 data from developer Kalvista Pharmaceuticals suggests that Ekterly (sebetralstat) is both safe and effective for young children, offering a needle-free alternative to the…

For people in Puerto Rico with hereditary angioedema (HAE), long-term treatment with Takhzyro (lanadelumab) is safe and effective for preventing swelling attacks, new real-world data show. Specifically, more than two years of treatment with the approved injection medication safely and effectively maintained low HAE attack rates among people of Hispanic or…

A woman in her 80s who had taken the same blood pressure medication for 11 years without issue suddenly developed a life-threatening reaction, marked by angioedema (swelling) in both her digestive tract and airway, a new case report reveals. The rare dual presentation initially mimicked a bowel obstruction, nearly…

A 56-year-old man’s recurring abdominal pain and bowel issues were finally traced back to a rare genetic condition, hereditary angioedema (HAE), according to a recent case report. Despite the patient’s age and lack of family history, genetic testing identified a mutation in the SERPING1 gene, and his symptoms were…

Use of Dawnzera (donidalorsen) — approved in the U.S. as a preventive treatment for hereditary angioedema (HAE) in patients ages 12 and older — led to sustained reductions in the rate of swelling attacks, accompanied by quality of life improvements, for as long as nearly four years among…

The U.S. Food and Drug Administration (FDA) has granted fast-track status to BW-20805, Argo Biopharma‘s long-acting investigational therapy for hereditary angioedema (HAE), which is intended to be given every three to six months to prevent swelling attacks in people with HAE. Most available HAE drugs must be taken…

Treatment with onvuzosiran (ADX-324), Adarx Pharmaceuticals’ experimental treatment for hereditary angioedema (HAE), was well tolerated and lowered kallikrein levels and the frequency of swelling attacks, according to interim data from a Phase 1/2 trial. The data were presented at the American Academy of Allergy, Asthma & Immunology annual scientific meeting,…